Performance in Initiating - Q3: 2016/2017 (1st January 2016 - 31st December 2016) - non HRA studies

Research Ethics Committee Reference Number	IRAS number	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	Date of First Patient Recruited	Duration between VRA and First Patient	Benchmark Met	Comments	Reasons for delay correspond to:
15/LO/1637	186118	WATER: Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue	14/01/2016	15/01/2016	01/02/2016	18	Yes	FP	Neither
15/LO/1015	182526	AQUA: Open label Phase4 study to examine the change of vision related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment.	10/02/2016	12/02/2016	19/05/2016	99	No	FP - Difficult to recruit to	Neither
15/SC/0409	183061	SEQUOIA: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration	28/01/2016	02/02/2016	17/03/2016	49	Yes	FP	Neither
13/EE/0038	111368	HALT-IT: Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial	11/02/2016	15/02/2016	14/03/2016	32	Yes	FP	Neither
14/NE/1144	154101	NATTINA: The NAtional Trial of Tonsillectomy IN Adults: a clinical and cost effectiveness study	08/03/2016	10/03/2016	12/05/2016	65	Yes	FP	Neither
14/SS/1025	156908	SUPPORT HF2: Home monitoring with integrated riskstratified disease management support versus home monitoring alone in patients with heart failure: a randomised controlled trial	22/02/2016	10/03/2016	25/04/2016	63	Yes	HWP	Neither
14/SC/0171	120104	Add-Aspirin: A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours	21/03/2016	22/04/2016			No	FP. Submitted early due to HRA changeover requirements	Neither
15/EM/0437	184390	COLUMBUS: Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration	21/03/2016	05/04/2016	16/06/2016	87	No	FP. Submitted early due to HRA changeover requirements	Neither

15/NI/00243	191267	EMPIRE: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis	30/03/2016	08/04/2016			No	FP. No patients consented yet.	Neither
16/SC/0158	187578	ALLIKAT: ll Ligaments Left In Knee Arthoplasty Trial	24/03/2016	12/07/2016	18/10/2016	208	No	FP. Submitted early due to HRA changeover requirement	Neither
15/EM/0552	189887	CIRCLE: A Phase 2, randomised, double masked, sham controlled, multi centre study to evaluate the efficacy and safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment in Subjects with Non Proliferative Diabetic Retinopathy	21/03/2016	14/07/2016	06/10/2016	199	No	FP. Submitted early due to HRA changeover requirement	Neither
15/NI/0177	167436	IVAN follow up: ive year observational follow-up of the IVAN trial cohort: a study of function and morphology	06/04/2016	20/07/2016	12/10/2016	189	No	FP. Submitted early due to HRA changeover requirement	Neither
16/WM/0001 (FP)	20668	WHITE4: World Hip Trauma Evaluation Four: A randomised controlled trial of the sliding hip screw versus XBolt dynamic plating system for the fixation of trochanteric fractures of the hip	21/03/2016	12/09/2016	25/10/2016	218	No	FP. Submitted early due to HRA changeover requirement	Neither
16/WM/0001 (WP)	20668	WHITE4: World Hip Trauma Evaluation Four: A randomised controlled trial of the sliding hip screw versus XBolt dynamic plating system for the fixation of trochanteric fractures of the hip	22/03/2016	12/09/2016	05/10/2016	197	No	WP. Submitted early due to HRA changeover requirement	Neither
15/EE/0010	138590	Pitches: Phase III trial of UDCA in ICP: V1	22/03/2016	22/03/2016	18/08/2016	149	No	FP. Lack of communication and documents/ access for pharmacy	Both